The American Society for Blood and Marrow Transplantation has published clinical practice recommendations related to the role of hematopoietic cell transplantation (HCT) for specific histologic subtypes of mature T-cell and NK/T-cell lymphomas.

Specifically, auto-HCT is recommended for:

• Front-line consolidation in PTCL-NOS, AITL, ALCL-ALK negative, NK/T-cell (disseminated), EATL, and hepatosplenic lymphomas.
• NK/T-cell (localized and disseminated), EATL, subcutaneous panniculitis-like T-cell, and ALCL-ALK positive lymphomas in relapsed-sensitive disease.
• PTCL-NOS, AITL, and ALCL-ALK negative if it was not performed in front-line.

Auto-HCT is not recommended for any of these histologic subtypes in primary or relapsed refractory stage. Meanwhile, allo-HCT is recommended for:

• Front-line consolidation in NK/T-cell (disseminated), ATLL (acute and lymphoma-type), and hepatosplenic lymphomas.
• For PTCL-NOS, AITL, ALCL-ALK negative, ALCL-ALK positive, NK/T-cell (localized and disseminated), ATLL (acute, lymphoma type, smoldering/chronic), MF/SS (advanced stage IIB-IVB or tumor stage/extracutaneous), EATL, subcutaneous panniculitis-like T-cell, and hepatosplenic lymphoma in relapsed-sensitive stage.
• For any aforementioned histologic subtypes in primary or relapsed refractory stage.